Dosage forms comprising polymers comprising different molecular weights

• US 5,326,571 A
• Filed: 09/04/1992
• Issued: 07/05/1994
• Est. Priority Date: 04/22/1991
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Swanson, David R., Barclay, Brian L., Wright, Jeri D.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Horne, Leon R.
• Application Number:
  US07/941,332
• Time in Patent Office: 669 Days
• Field of Search: 424/473, 424/472, 424/468
• US Class Current: 424/473
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

A dosage form is disclosed comprising a wall surrounding a compartment, which comprises a first composition comprising a carboxymethylcellulose and a second composition comprising a higher molecular weight carboxymethylcellulose. The first composition comprises a dosage amount of drug that delivers from the dosage form at a controlled rate over time.

Claims

1. A dosage form for the administration of a drug to a patient, the dosage form comprising:

(a) a first composition comprising 10 ng to 750 mg of drug;

(b) a second composition for pushing the first composition from the dosage form;

(c) a wall surrounding the first and second compositions, said wall comprising at least in part a composition permeable to the passage of fluid; and

,

(d) at least one exit means in the wall for delivering the drug from the dosage form to the patient; and

wherein said,

(e) first composition comprises a carboxymethylcellulose comprising a 10,000 to 300,000 molecular weight; and

said,

(f) second composition comprising a carboxymethylcellulose comprising a molecular weight greater than 300,000 to 1,200,000; and

wherein said

(g) first and second compositions, when the dosage form is in operation, cooperate to deliver substantially all the drug in the dosage form to the patient over time.

2. The dosage form for administering the drug to the patient according to claim 1, wherein the carboxymethylcellulose in the first composition is sodium carboxymethylcellulose.

3. The dosage form for administering the drug to the patient according to claim 1, wherein the carboxymethylcellulose in the second composition is sodium carboxymethylcellulose.

4. The dosage form for administering the drug to the patient according to claim 1, wherein the drug is a calcium channel blocker.

5. The dosage form for administering the drug to the patient according to claim 1, wherein the drug is a member selected from the group consisting of nifedipine, verapamil, diltiazem, bepridil, nicardipine, nitredipine, isradipine, and niludepine.

6. The dosage form for administering the drug to the patient according to claim 1, wherein the drug is a member selected from the group consisting of nisoldipine, felodipine, cinnarizine, flunarizine, perhexiline and amlodipine.

7. The dosage form for administering the drug to the patient according to claim 1, wherein the drug in the first composition is nifedipine and the composition additionally comprises hydroxypropylcellulose.

8. The dosage form for administering the drug to the patient according to claim 1, wherein the drug in the first composition is nifedipine, and the composition additionally comprises polyvinylpyrrolidone.

9. A first composition comprising 10 ng to 750 mg of a drug and a carboxymethylcellulose comprising a 10,000 to 300,000 molecular weight;

a second composition comprising a carboxymethylcellulose comprising a molecular weight greater than 300,000 to 1,200,000; and

wherein said first composition and second composition are in bilayer arrangement.

10. A dosage form for administering drug to a patient in need of therapy wherein, the dosage form comprises:

(a) a first composition comprising 10 ng to 750 mg of a drug, riboflavin, a surface active agent and a carboxymethylcellulose comprising a 10,000 to 300,000 molecular weight;

(b) a second composition for pushing the first composition from the dosage form comprising a carboxymethylcellulose comprising a molecular weight greater than 300,000 to 1,200,000; and

,

(c) at least one exit means in the wall for delivering the drug from the dosage form to the patient.

11. The dosage form for administering the drug to the patient according to claim 10, wherein the drug is a member selected from the group consisting of nifedipine, verapamil, diltiazem, bepridil, nicardipine, nitredipine, isradipine and niludepine.

12. The dosage form for administering the drug to the patient according to claim 10, wherein the drug is a member selected from the group consisting of nisoldipine, felodipine, cinnarizine, flunarizine, perhexiline and amlodipine.

13. A first composition comprising 10 ng to 750 mg of a drug, riboflavin, a surface active agent and a carboxymethylcellulose comprising a 10,000 to 300,000 molecular weight;

a second composition comprising a carboxymethylcellulose comprising a molecular weight greater than 300,000 to 1,200,000; and

wherein said first composition and second composition are in bilayer arrangement. X